公开(公告)号：WO2015195835A2

公开(公告)日：2015-12-23

申请号：PCT/US2015036284

申请日：2015-06-17

Applicant: UNIV CALIFORNIA ,  MEDIMMUNE LLC ,  MEDIMMUNE LTD

Inventor： NISHIMURA STEPHEN ,  LOU JIANLONG ,  CORMIER ANTHONY ,  BARON JODY LYNN ,  MARKS JAMES D ,  MURRAY LYNNE ,  TSUI PING ,  WU YANLI

IPC: C07K16/18

CPC classification number: C07K16/2839 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76

Abstract: Provided herein are antibodies specific for integrin αvβ8 that change the conformation of β8 so that, upon binding, the ability of αvβ8 to induce release of active, mature TGFβ peptide is inhibited.

Abstract translation: 本文提供对整合素αvβ8特异性的抗体，其改变β8的构象，使得在结合时，αvβ8诱导活性成熟TGFβ肽释放的能力被抑制。

公开(公告)号：WO2013034660A9

公开(公告)日：2013-09-19

申请号：PCT/EP2012067454

申请日：2012-09-06

Applicant: MEDIMMUNE LTD ,  CAMBRIDGE ENTPR LTD ,  ELVIN JOHN ,  HUNTINGTON CATHERINE ,  TROWSDALE JOHN ,  BARROW ALEXANDER ,  CAO HUAN

Inventor： ELVIN JOHN ,  HUNTINGTON CATHERINE ,  TROWSDALE JOHN ,  BARROW ALEXANDER ,  CAO HUAN

IPC: A61K39/395 ,  C07K16/28

CPC classification number: C07K16/2803 ,  C07K16/30 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/77

Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.

Abstract translation: 本公开涉及抗Siglec-15抗体及其用途，特别是用于治疗白血病如急性骨髓性白血病。

公开(公告)号：WO2013070615A8

公开(公告)日：2013-06-20

申请号：PCT/US2012063722

申请日：2012-11-06

Applicant: MEDIMMUNE LLC ,  MEDIMMUNE LTD

Inventor： DIGIANDOMENICO ANTONIO ,  WARRENER PAUL ,  STOVER CHARLES ,  SELLMAN BRET ,  MINTER RALPH ,  GUILLARD SANDRINE ,  RUST STEVEN ,  TOMICH MLADEN ,  VENKATRAMAN VIGNESH ,  VARKEY REENA ,  PENG LI ,  DAMSCHRODER MELISSA ,  CHOWDHURY PARTHA ,  DIMASI NAZZARENO ,  FLEMING RYAN ,  BEZABEH BINYAM ,  GAO CHANGSHOU

IPC: A61K39/395 ,  A61K39/00 ,  C07K16/00 ,  C12P21/08

CPC classification number: C07K16/1214 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

Abstract: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.

Abstract translation: 本公开涉及包含抗Pseudomonas Ps1和PcrV结合分子和相关组合物的组合疗法，用于预防和治疗假单胞菌属感染。

公开(公告)号：WO2012170807A3

公开(公告)日：2013-03-28

申请号：PCT/US2012041538

申请日：2012-06-08

Applicant: MEDIMMUNE LLC ,  DIGIANDOMENICO ANTONIO ,  WARRENER PAUL G ,  STOVER CHARLES K ,  SELLMAN BRET ,  MEDIMMUNE LTD ,  GUILLARD SANDRINE ,  MINTER RALPH ,  RUST STEVEN ,  TOMICH MLADEN

Inventor： DIGIANDOMENICO ANTONIO ,  WARRENER PAUL G ,  STOVER CHARLES K ,  SELLMAN BRET ,  GUILLARD SANDRINE ,  MINTER RALPH ,  RUST STEVEN ,  TOMICH MLADEN

IPC: C07K16/12 ,  C12P21/00

CPC classification number: C07K16/1214 ,  A61K38/00 ,  A61K47/6811 ,  A61K47/6835 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: This disclosure relates to an anti-Pseudomonas Psl binding molecules and uses thereof, in particular in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.

Abstract translation: 本公开涉及抗假单胞菌Ps1结合分子及其用途，特别是预防和治疗假单胞菌属（Pseudomonas）感染。 此外，本公开提供了预防和治疗假单胞菌属感染的组合物和方法。

公开(公告)号：WO2010070346A3

公开(公告)日：2010-10-14

申请号：PCT/GB2009051728

申请日：2009-12-17

Applicant: MEDIMMUNE LTD ,  COHEN SUZANNE ,  DOBSON CLAIRE LOUISE ,  ERIKSSON PER-OLOF FREDRIK ,  LANE DEBORAH LOUISE ,  VON WACHENFELDT KARIN

Inventor： COHEN SUZANNE ,  DOBSON CLAIRE LOUISE ,  ERIKSSON PER-OLOF FREDRIK ,  LANE DEBORAH LOUISE ,  VON WACHENFELDT KARIN

IPC: C07K16/28

CPC classification number: C07K16/2866 ,  C07K2317/21 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  C07K2319/32

Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4Ra) in particular Fc variant formats, and their therapeutic use e.g. in treating or preventing disorders associated with IL-4Ra, IL-4 and/or IL-13, examples of which are asthma and COPD.

Abstract translation: 用于白细胞介素（IL）-4受体α（IL-4Ra），特别是Fc变体形式的结合成员，特别是抗体分子，以及它们的治疗用途。 在治疗或预防与IL-4Ra，IL-4和/或IL-13相关的疾病中，其实例是哮喘和COPD。

公开(公告)号：WO2008114011A3

公开(公告)日：2008-11-20

申请号：PCT/GB2008000967

申请日：2008-03-19

Applicant: MEDIMMUNE LTD ,  GULER-GANE GULIN ,  HOLGATE ROBERT GEORGE EDWARD ,  JERMUTUS LUTZ ULRICH JOCHEN WILHELM ,  LEVENS JACQUELINE MICHAELA ,  LUND JOHN NORMAN ,  STEWART ROSS ANTHONY ,  THOM ALBERT GEORGE ,  WEBSTER CARL

Inventor： GULER-GANE GULIN ,  HOLGATE ROBERT GEORGE EDWARD ,  JERMUTUS LUTZ ULRICH JOCHEN WILHELM ,  LEVENS JACQUELINE MICHAELA ,  LUND JOHN NORMAN ,  STEWART ROSS ANTHONY ,  THOM ALBERT GEORGE ,  WEBSTER CARL

IPC: C12N15/10 ,  A61K39/395 ,  A61P35/00 ,  C40B50/10

CPC classification number: C07K16/00 ,  C07K16/2887 ,  C07K2317/72 ,  C07K2317/732 ,  C40B30/04 ,  C40B40/10 ,  C40B50/10

Abstract: The present invention relates to methods for selecting, obtaining or producing Fc variant polypeptides which show altered recognition for an Fc ligand (e.g., Fc?R, CIq). Additionally, the Fc variant polypeptides may have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variant polypeptides particularly for therapeutic purposes.

Abstract translation: 本发明涉及用于选择，获得或产生对Fc配体（例如FcγR，C1q）显示改变的识别的Fc变体多肽的方法。 另外，Fc变体多肽可能具有改变的抗体依赖性细胞介导的细胞毒性（ADCC）和/或补体依赖性细胞毒性（CDC）活性。 本发明还提供了用于应用所述Fc变体多肽的方法和方案，特别是用于治疗目的。

公开(公告)号：WO2016097315A3

公开(公告)日：2016-08-11

申请号：PCT/EP2015080539

申请日：2015-12-18

Applicant: MEDIMMUNE LTD

Inventor： WEBSTER CARL INNES ,  THOM ALBERT GEORGE ,  JERMUTUS LUTZ U ,  HATCHER JONATHAN P

IPC: C07K16/40 ,  A61K47/48 ,  C07K14/00

CPC classification number: C07K16/40 ,  A61K47/6811 ,  A61K47/6849 ,  A61K2039/505 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/77 ,  C07K2317/94

Abstract: The disclosure provides transporter molecules capable of carrying agents of interest across the blood brain barrier. Also provided are polynucleotides encoding transporter molecules, methods making transporter molecules, and methods of using transporter molecules, e.g., for the diagnosis, prevention, or treatment of central nervous system diseases, disorders, or injuries.

Abstract translation: 本公开提供了能够跨血脑屏障携带感兴趣试剂的转运蛋白分子。 还提供了编码转运蛋白分子的多核苷酸，制备转运蛋白分子的方法和使用转运蛋白分子的方法，例如用于诊断，预防或治疗中枢神经系统疾病，病症或损伤。

公开(公告)号：WO2015169811A3

公开(公告)日：2016-02-04

申请号：PCT/EP2015059876

申请日：2015-05-05

Applicant: MEDIMMUNE LTD

Inventor： CARROLL DANIELLE ,  ROSSANT CHRIS ,  BARRY SIMON THOMAS

IPC: C07K16/28

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92

Abstract: This disclosure relates to an anti-CXCR2 binding molecules and uses thereof, in particular in treatment of cancers and inflammatory diseases. Furthermore, the disclosure provides compositions and methods for treating cancers and inflammatory diseases.

Abstract translation: 本公开涉及抗CXCR2结合分子及其用途，特别是治疗癌症和炎性疾病。 此外，本公开提供了治疗癌症和炎性疾病的组合物和方法。

公开(公告)号：WO2011033005A3

公开(公告)日：2011-05-12

申请号：PCT/EP2010063583

申请日：2010-09-15

Applicant: MEDIMMUNE LTD ,  DARAMOLA OLALEKAN ,  DEAN GREGORY ,  HATTON DIANE ,  STEVENSON JESSICA

Inventor： DARAMOLA OLALEKAN ,  DEAN GREGORY ,  HATTON DIANE ,  STEVENSON JESSICA

IPC: C12N15/85 ,  C12N7/02

CPC classification number: C12N7/00 ,  C07K14/005 ,  C07K16/00 ,  C07K2317/14 ,  C12N2710/16222

Abstract: This invention relates to the transient expression of heterologous polypeptides in mammalian cell lines. Specifically it relates to an expression-enhanced cell line derived from a parent cell line, the expression-enhanced cell line comprising nucleic acid encoding Epstein-Barr Virus Nuclear Antigen 1 or a functional derivative, analogue, or variant thereof; and further comprising: (a) a nucleic acid encoding an exogenous glutamine synthetase; (b) a nucleic acid encoding an endogenous glutamine synthetase, wherein the endogenous glutamine is arranged to have enhanced enzymatic activity and/or enhanced expression relative to the parent cell line under comparable conditions; or (c) both (a) and (b).

Abstract translation: 本发明涉及哺乳动物细胞系中异源多肽的瞬时表达。 具体涉及源自亲本细胞系的表达增强的细胞系，所述表达增强的细胞系包含编码爱泼斯坦 - 巴尔病毒核抗原1或其功能性衍生物，类似物或变体的核酸; 并且进一步包含：（a）编码外源谷氨酰胺合成酶的核酸; （b）编码内源谷氨酰胺合成酶的核酸，其中所述内源谷氨酰胺被排列成在相当的条件下相对于亲本细胞系具有增强的酶活性和/或增强的表达; 或（c）（a）和（b）。

公开(公告)号：WO2010032059A3

公开(公告)日：2010-06-24

申请号：PCT/GB2009051216

申请日：2009-09-18

Applicant: MEDIMMUNE LLC ,  MEDIMMUNE LTD ,  BABCOOK JOHN ,  BARRY SIMON THOMAS ,  GAZIT-BORNSTEIN GADI ,  LAING NAOMI ,  ZHOU QING

Inventor： BABCOOK JOHN ,  BARRY SIMON THOMAS ,  GAZIT-BORNSTEIN GADI ,  LAING NAOMI ,  ZHOU QING

IPC: C07K16/28 ,  A61K39/395

CPC classification number: C07K16/2896 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92

Abstract: The invention relates to targeted binding agents against CD105 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to CD105. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of CD105 and as diagnostics.

Abstract translation: 本发明涉及针对CD105的靶向结合剂及其用途。 更具体地，本发明涉及针对CD105的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与CD105的活性和/或过度产生相关的疾病和作为诊断。